Ropeginterferon alfa-2b Clinical Trials (2026): 27 Studies for Polycythemia Vera & Myelofibrosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
27 Ropeginterferon alfa-2b clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 20 indications (including Polycythemia Vera & Myelofibrosis) and 2,268 total planned enrollment. 6 Phase 3 Ropeginterferon alfa-2b trials and 10 Phase 2, 2 Phase 4 are listed. 11 Ropeginterferon alfa-2b clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07468916 (Sep 2032).
Where to Participate: All Ropeginterferon alfa-2b Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Ropeginterferon alfa-2btrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Moffitt Cancer Center | Tampa33612 | NCT07047885 | Map |
Ropeginterferon alfa-2b clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | 4 | |||
| P1/P2 | 1 | 1 | |||||
| P2 | 2 | 2 | 1 | 1 | 2 | 2 | 10 |
| P2/P3 | 1 | 1 | |||||
| P3 | 2 | 3 | 1 | 6 | |||
| P4 | 1 | 1 | 2 | ||||
| N/A | 1 | 1 | 1 | 3 |
Recruiting Ropeginterferon alfa-2b clinical trials (11)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | P2 | Atypical Chronic Myeloid Leukemia | 35 | Sep 2026 |
| NCT07249840 | Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis | P1 | JAK2 Mutation | 12 | Aug 2026 |
| NCT07521046 | Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) | P1 | Myelofibrosis | 15 | May 2026 |
| NCT07269470 | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | P2 | Chronic Myeloid Leukemia | 40 | Nov 2026 |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | P3 | Primary Myelofibrosis | 150 | Jul 2025 |
| NCT07047885 | CTCLRopeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | P1 | Cutaneous T Cell Lymphoma | 38 | Aug 2025 |
| NCT06770842 | Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis | P2 | Primary Myelofibrosis (PMF) | 20 | Mar 2025 |
| NCT06290765 | PVEfficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera | P4 | Polycythemia Vera | 70 | Feb 2026 |
| NCT05731245 | Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis | P2 | Pre-fibrotic Myelofibrosis | 50 | Feb 2023 |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | P3 | Polycythemia Vera (PV) | 67 | Jan 2021 |
| NCT07282132 | MIRROREvaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study | — | Polycytemia Vera | 150 | Jan 2026 |
Ropeginterferon alfa-2b clinical trials by indication
Polycythemia Vera (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05481151 | — | P3 | active not recruiting | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV |
| NCT05485948 | — | P2 | active not recruiting | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU |
| NCT06290765 | PV | P4 | not yet recruiting | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera |
| NCT06506084 | ROPEG-PV | N/A | active not recruiting | Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
Chronic Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07269470 | — | P2 | not yet recruiting | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase |
| NCT03831776 | BosuPeg | P2 | completed | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis |
Primary Myelofibrosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06468033 | — | P3 | recruiting | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk |
| NCT02370329 | — | P2 | terminated | P1101 in Treating Patients With Myelofibrosis |
COVID-19 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05808322 | — | P2/P3 | unknown | Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities |
| NCT05770466 | — | P3 | completed | Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19. |
Essential Thrombocythemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04285086 | SURPASS ET | P3 | active not recruiting | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance |
| NCT05482971 | — | P2 | active not recruiting | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET |
Atypical Chronic Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07468916 | — | P2 | not yet recruiting | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia |
JAK2 Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07249840 | — | P1 | not yet recruiting | Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis |
Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07521046 | — | P1 | not yet recruiting | Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) |
Polycytemia Vera (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07282132 | MIRROR | N/A | not yet recruiting | Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study |
Cutaneous T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07047885 | CTCL | P1 | recruiting | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) |
Primary Myelofibrosis (PMF) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06770842 | — | P2 | recruiting | Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis |
Essential Thrombocythaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06514807 | — | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients |
Hepatitis D (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05467553 | — | P2 | unknown | A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection |
Pre-fibrotic Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05731245 | — | P2 | recruiting | Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis |
CML (Chronic Myelogenous Leukemia) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07105319 | ROPEG | P4 | completed | Ropeginterferon for Treatment Free Remission |
Primary Myelofibrosis, Prefibrotic Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04988815 | — | P2 | unknown | Ropeginterferon Alfa 2b for Early Myelofibrosis |
Chronic Hepatitis B Virus Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05494528 | — | N/A | unknown | Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy |
Polycythemia Vera (PV) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04655092 | — | P3 | recruiting | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients |
Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04233840 | — | P1/P2 | unknown | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03546465 | — | P1 | completed | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects |
Ropeginterferon alfa-2b pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PV | NCT06290765 | P4 | not yet recruiting | Polycythemia Vera | 70 | — |
| ROPEG | NCT07105319 | P4 | completed | CML (Chronic Myelogenous Leukemia) | 65 | — |
| SURPASS ET | NCT04285086 | P3 | active not recruiting | Essential Thrombocythemia | 174 | PMID 35924546 |
| BosuPeg | NCT03831776 | P2 | completed | Chronic Myeloid Leukemia | 212 | — |
Terminated and withdrawn Ropeginterferon alfa-2b trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT02370329terminatedP1101 in Treating Patients With Myelofibrosis
All Ropeginterferon alfa-2b trials (27)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | P2 | not yet recruiting | 35 | Jonsson Comprehensive Cancer Center | Sep 2026 | |
| NCT07249840 | Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis | P1 | not yet recruiting | 12 | Brigham and Women's Hospital | Aug 2026 | |
| NCT07521046 | Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) | P1 | not yet recruiting | 15 | University of Utah | May 2026 | |
| NCT07269470 | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | P2 | not yet recruiting | 40 | M.D. Anderson Cancer Center | Nov 2026 | |
| NCT04285086 | SURPASS ET | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | P3 | active not recruiting | 174 | PharmaEssentia | Aug 2020 |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | P3 | recruiting | 150 | PharmaEssentia | Jul 2025 | |
| NCT07047885 | CTCL | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | P1 | recruiting | 38 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2025 |
| NCT06514807 | A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients | P3 | active not recruiting | 117 | AOP Orphan Pharmaceuticals AG | Dec 2023 | |
| NCT06770842 | Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis | P2 | recruiting | 20 | The University of Hong Kong | Mar 2025 | |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | P3 | active not recruiting | 111 | PharmaEssentia | Oct 2022 | |
| NCT05485948 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | P2 | active not recruiting | 49 | PharmaEssentia | Oct 2021 | |
| NCT06290765 | PV | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera | P4 | not yet recruiting | 70 | PharmaEssentia | Feb 2026 |
| NCT05482971 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | P2 | active not recruiting | 91 | PharmaEssentia | Sep 2022 | |
| NCT06506084 | ROPEG-PV | Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) | — | active not recruiting | 319 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Sep 2022 |
| NCT05731245 | Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis | P2 | recruiting | 50 | National Taiwan University Hospital | Feb 2023 | |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | P3 | recruiting | 67 | PharmaEssentia Japan K.K. | Jan 2021 | |
| NCT07282132 | MIRROR | Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study | — | not yet recruiting | 150 | Federico II University | Jan 2026 |
| NCT04988815 | Ropeginterferon Alfa 2b for Early Myelofibrosis | P2 | unknown | 50 | The University of Hong Kong | Sep 2021 | |
| NCT05467553 | A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection | P2 | unknown | 30 | National Taiwan University Hospital | Feb 2023 | |
| NCT07105319 | ROPEG | Ropeginterferon for Treatment Free Remission | P4 | completed | 65 | Dong-Wook Kim | Nov 2021 |
| NCT05808322 | Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities | P2/P3 | unknown | 60 | National Taiwan University Hospital | May 2023 | |
| NCT03831776 | BosuPeg | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis | P2 | completed | 212 | St. Olavs Hospital | Mar 2019 |
| NCT05494528 | Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy | N/A | unknown | 90 | National Taiwan University Hospital | May 2021 | |
| NCT02370329 | P1101 in Treating Patients With Myelofibrosis | P2 | terminated | 11 | Mayo Clinic | Aug 2015 | |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | P1/P2 | unknown | 72 | National Taiwan University Hospital | Feb 2019 | |
| NCT05770466 | Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19. | P3 | completed | 134 | National Taiwan University Hospital | Apr 2022 | |
| NCT03546465 | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects | P1 | completed | 36 | PharmaEssentia Japan K.K. | May 2018 |
Ropeginterferon alfa-2b clinical trials: frequently asked questions
- How many Ropeginterferon alfa-2b clinical trials are there?
- 27 Ropeginterferon alfa-2b clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 4 are marked completed.
- Are Ropeginterferon alfa-2b clinical trials recruiting in 2026?
- Yes — 5 Ropeginterferon alfa-2b trials are actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ropeginterferon alfa-2b being studied for?
- Ropeginterferon alfa-2b is being studied for Polycythemia Vera, Myelofibrosis, Myeloproliferative Neoplasm, Chronic Myeloid Leukemia, COVID-19 and 23 more. The trials are grouped by indication on this page.
- What phase is Ropeginterferon alfa-2b in?
- Ropeginterferon alfa-2b clinical trials span 2 Phase 4, 6 Phase 3, 10 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ropeginterferon alfa-2b clinical trials?
- The lead sponsor across the most Ropeginterferon alfa-2b trials is National Taiwan University Hospital, with 14 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ropeginterferon alfa-2bas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: